Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01 Meeting Abstract
| Authors: | Li, B. T.; Smit, E. F.; Goto, Y.; Nakagawa, K.; Goto, K.; Mazieres, J.; Uprety, D.; Bazhenova, L.; Saltos, A.; Felip, E.; Pacheco, J.; Pérol, M.; Paz-Ares, L.; Saxena, K.; Shiga, R.; Cheng, Y.; Yan, Q.; Planchard, D.; Jänne, P. A. |
| Abstract Title: | Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01 |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S995 |
| End Page: | S996 |
| Language: | English |
| ACCESSION: | WOS:000866211601244 |
| DOI: | 10.1016/j.annonc.2022.07.1104 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 976P -- Source: Wos |
